Systemic Vasculitis

Systemic Vasculitis — Internal Medicine

How it begins

Clasificación de Chapel Hill 2012, fisiopatología inmune, diagnóstico diferencial y tratamiento basado en evidencia de las principales vasculitis sistémicas primarias y secundarias, con especial énfasis en las vasculitis ANCA-asociadas, vasculitis de grandes vasos y síndromes de vasculitis de pequeño vaso.

What it covers

1. Introduction, Classification and Pathophysiology
2. · 1.1 Chapel Hill Classification — Nomenclature 2012
3. · 1.2 ANCA — Anti-Neutrophil Cytoplasmic Antibodies
4. Large Vessel Vasculitis
5. · 2.1 Giant Cell Arteritis (GCA) — Horton's Arteritis
6. · 2.2 Takayasu arteritis (TA)
7. Medium Vessel Vasculitis
8. · 3.1 Polyarteritis Nodosa (PAN)
9. · 3.2 Kawasaki disease
10. ANCA-Associated Vasculitis (AAV)
11. · 4.1 Granulomatosis with Polyangiitis (GPA / Wegener)
12. · 4.2 Microscopic Polyangiitis (MAP)
13. · 4.3 Eosinophilic Granulomatosis with Polyangiitis (GEPA / Churg-Strauss)
14. Vasculitis due to Small Vessel Immune Complexes
15. · 5.1 IgA Vasculitis (Henoch-Schönlein Purpura, VIgA)
16. · 5.2 Cryoglobulinemic Vasculitis
17. · 5.3 Anti-GBM Disease (Goodpasture Syndrome)
18. Variable Vessel Vasculitis — Behçet and Cogan
19. · 6.1 Behçet's disease
20. · 6.2 Cogan syndrome
21. Differential Diagnosis of Systemic Vasculitis
22. Immunosuppressive Treatment — Principles and Protocols
23. · 8.1 Induction of Remission in AAV
24. · 8.2 Remission Maintenance
25. · 8.3 Biological Therapy in Vasculitis — Summary of Evidence
26. Complications, Prognosis and Follow-up
27. · 9.1 Activity and Damage Tools
28. · 9.2 Treatment Toxicity — Common Complications
29. · 9.3 Prognosis of the Main Vasculitis